Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAA) is a special purpose acquisition company focused on the domestic pharmaceutical and life sciences manufacturing sector. The company filed a Form 425 on July 20, 2026, a communication type associated with proposed business combinations, indicating that DMAA is actively progressing toward a merger or acquisition target announcement. The SPAC's stated focus on American-made drug manufacturing reflects broader policy and supply-chain trends in the domestic pharmaceutical industry. For the full filing history, sponsor details, deal timeline, and real-time status updates on DMAA, sign up for complete data access at SpacDesk.